{"success":true,"data":{"pressRelease":{"id":"19015","rtpr_id":"nPn2nbN0Ba","ticker":"NBIX","exchange":"NASDAQ","all_tickers":["NBIX"],"title":"Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment","author":"PR Newswire","published_at":"2026-05-04T12:30:03.325Z","article_body":"Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment\n\nPR Newswire\n\nSAN DIEGO, May 4, 2026\n\n * Approximately 1 in 5 surveyed working adults with tardive dyskinesia reported\nquitting their job due to untreated involuntary movements(1)\n * Respondents also reported missing an average of 8 hours of work or school per\nweek due to tardive dyskinesia prior to treatment(1)\n * Findings released during Tardive Dyskinesia Awareness Week\nSAN DIEGO, May 4, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678890-1&h=1463423739&u=https%3A%2F%2Fwww.neurocrine.com%2F&a=Neurocrine+Biosciences%2C+Inc.)\n(Nasdaq: NBIX) today announced the release of findings from a new survey\nrevealing the significant impact of tardive dyskinesia (TD) on people's\nability to work, go to school, volunteer or actively look for employment.\nAbout one in five surveyed working adults with TD reported quitting their job\ndue to TD symptoms prior to treatment.(1) Findings are released in recognition\nof Tardive Dyskinesia Awareness Week (May 3-9) to underscore the importance of\nincreased awareness, early recognition and appropriate management of TD.\n\n(https://mma.prnewswire.com/media/678850/Neurocrine_Biosciences_Logo.html)\n\n\"These findings highlight how uncontrolled, involuntary movements associated\nwith tardive dyskinesia can lead to reduced job responsibilities or even loss\nof employment,\" said Sanjay Keswani, M.D., Chief Medical Officer, Neurocrine\nBiosciences. \"This reinforces the importance of routine screening for tardive\ndyskinesia in clinical practice, including evaluation of its impact on\npatients' and caregivers' lives so that appropriate treatment can be\nconsidered to help reduce this burden.\"\n\nThe quantitative survey was conducted online in the United States by Ipsos on\nbehalf of Neurocrine Biosciences from January 15 to February 17, 2026. It\nincluded 100 individuals: 70 adults (average age 47 years) who have been\ndiagnosed with TD by a healthcare provider and 30 caregivers of people with TD\n(average age 42 years). Employment-related findings are based on the 59\nrespondents diagnosed with TD who met the study's employment criteria*;\ncaregiver burden findings are based on 19 caregivers who completed follow-up\nquestions about the impact of TD on their own lives.(1)\n\nThe survey found that of 59 adults with TD who were working, in school,\nvolunteering or actively looking for employment(1):\n\n * Approximately one in five, or 12 surveyed working adults, reported quitting\ntheir job primarily due to TD symptoms.\n * 19 reported having to step down from their work-related responsibilities or\nchange job responsibilities because of TD symptoms.\n * All 59 respondents reported missing an average of eight hours of work or\nschool during the week prior to starting TD treatment.\nAmong the 19 surveyed working caregivers, many reported missing work or having\ninterruptions to their own lives due to their loved ones' TD symptoms prior to\nstarting treatment.\n\nEarlier screening and accurate diagnosis of TD are critical to ensuring\npatients, who are already managing their underlying serious mental illness,\nreceive appropriate, evidence-based care. The American Psychiatric\nAssociation clinical guidelines recommend first-line, FDA-approved treatment\nwith a vesicular monoamine transporter 2 (VMAT2) inhibitor for those with\nmoderate to severe TD or those with mild TD if the movements are\ndisruptive.(2) Despite these recommendations, only an estimated one out of 10\nindividuals with TD are treated with a VMAT2 inhibitor.(3)\n\n\"Many people may not recognize that their uncontrolled movements are symptoms\nof tardive dyskinesia, which can affect many aspects of everyday life for\nadults, including their ability to work or go to school and, for many\nindividuals, constitutes a key component of their identity,\" said Josie\nCooper, Executive Director of the Movement Disorders Policy Coalition. \"During\nTD Awareness Week, these findings highlight the real-world burden experienced\nby patients and care partners and reinforce why awareness, recognition and\nappropriate management of TD are so important. We hope they encourage people\nto start informed conversations with healthcare providers and seek support.\"\n\nEstablished in 2018, Tardive Dyskinesia Awareness Week unites the mental\nhealth community to recognize the full impact of TD, including its physical,\nsocial and emotional effects on people living with the condition and the need\nfor routine screening, earlier diagnosis and treatment.(4) TD is estimated to\naffect at least 800,000 adults in the U.S. living with mental illness, yet\napproximately 60% remain undiagnosed, meaning many individuals living with TD\nmay not be identified or appropriately managed.(3,5) TD movements can result\nin both physical and emotional consequences, resulting in meaningful burden on\none's employment and ability to maintain work.(1,4) For more information,\nvisit Neurocrine.com/TD-Awareness\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678890-1&h=1851618768&u=https%3A%2F%2Fwww.neurocrine.com%2Ftd-awareness%2F&a=Neurocrine.com%2FTD-Awareness)\n.\n\n*Employment-related findings are based on the low base size of 59 respondents\ndiagnosed with TD who met the study's employment criteria. Exercise caution\nwhen interpreting results.\n\nSurvey Methodology\nThe research was conducted online in the United States by Ipsos on behalf of\nNeurocrine Biosciences among 100 individuals, including 70 people who have\nbeen diagnosed with tardive dyskinesia (TD) by a healthcare provider and 30\ncaregivers of people with TD. Of those individuals, 59 met employment\ncriteria, defined as being currently employed (part time or full time), a\nstudent, a volunteer or unemployed but actively looking for work. Caregivers\nwere defined as a partner/spouse or family member who is not a professional\ncaregiver paid by the patient for their services. The 20-minute quantitative\nonline survey was conducted January 15-February 17, 2026.\n\nAbout Ipsos\nIpsos is one of the largest market research and polling companies globally,\noperating in 90 markets and employing nearly 20,000 people. Ipsos is comprised\nof passionately curious research professionals, analysts and scientists and\nhave built unique multi-specialist capabilities that provide true\nunderstanding and powerful insights into the actions, opinions and motivations\nof citizens, consumers, patients, customers or employees.\n\nAbout Tardive Dyskinesia Awareness Week\nThe first Tardive Dyskinesia (TD) Awareness Week took place in 2018. Over the\nyears, all 50 states, Washington, D.C. and multiple mental health advocacy\norganizations continue to recognize the first full week of May as TD Awareness\nWeek. TD is a chronic condition that is unlikely to improve without treatment\nand is estimated to affect at least 800,000 adults in the United States. TD\nAwareness Week unites the mental health community to recognize the physical,\nsocial and emotional effects of TD and reinforces the importance of early\nassessment by healthcare providers and discussion of available FDA-approved\ntreatment.\n\nNeurocrine Biosciences, Inc. remains focused on TD education, empowering\nindividuals to act and elevating the importance of routine screening for\nearlier diagnosis and appropriate treatment. As part of Neurocrine\nBiosciences' commitment to TD education, more information is available at\nNeurocrine.com/TD-Awareness\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678890-1&h=266837859&u=https%3A%2F%2Fwww.neurocrine.com%2FTD-Awareness%2F&a=Neurocrine.com%2FTD-Awareness)\n, and resources are available at TalkAboutTD.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678890-1&h=3626663216&u=https%3A%2F%2Fwww.talkabouttd.com%2F&a=TalkAboutTD.com)\n. These resources can help patients and care partners understand TD and\nrecognize its symptoms, seek support and have conversations with their\nhealthcare providers about ways to manage the condition, including treatment\noptions. Healthcare professionals can also visit MIND-TD.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678890-1&h=3804491251&u=https%3A%2F%2Fwww.mind-td.com%2F&a=MIND-TD.com)\nto learn about differential diagnosis of TD and other movement disorders. For\nmore information, follow and join the conversation online by sharing\n#TDAwarenessWeek #Screen4TD.\n\nAbout Tardive Dyskinesia\nTardive dyskinesia (TD) is a movement disorder that is characterized by\nuncontrolled, abnormal and repetitive movements of the face, torso and/or\nother body parts, which may be disruptive and negatively impact patients. The\ncondition is associated with taking certain kinds of mental health medicines\n(antipsychotics) that help control dopamine receptors in the brain. Taking\nantipsychotics commonly prescribed to treat mental illnesses such as major\ndepressive disorder, bipolar disorder, schizophrenia and schizoaffective\ndisorder and other prescription medicines (metoclopramide and\nprochlorperazine) used to treat gastrointestinal disorders are associated with\nTD. In patients with TD, these treatments are thought to result in irregular\ndopamine signaling in a region of the brain that controls movement. The\nsymptoms of TD can be mild to severe and are often persistent and\nirreversible. TD is estimated to affect at least 800,000 adults in the U.S.\n\nAbout Neurocrine Biosciences, Inc.\nNeurocrine Biosciences is a leading biopharmaceutical company with a simple\npurpose: to relieve suffering for people with great needs. We are dedicated to\ndiscovering and developing life-changing treatments for patients with\nunder-addressed neurological, endocrine, psychiatric and immunological\ndisorders. The company's diverse portfolio includes FDA-approved treatments\nfor tardive dyskinesia, chorea associated with Huntington's disease, classic\ncongenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well\nas a robust pipeline including multiple compounds in mid- to late-phase\nclinical development across our core therapeutic areas. For three decades, we\nhave applied our unique insight into neuroscience and the interconnections\nbetween brain and body systems to treat complex conditions. We relentlessly\npursue medicines to ease the burden of debilitating diseases and disorders\nbecause you deserve brave science. For more information, visit neurocrine.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678890-1&h=1504702785&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4637976-1%26h%3D778289524%26u%3Dhttps%253A%252F%252Fwww.neurocrine.com%252F%26a%3Dneurocrine.com&a=neurocrine.com)\n, and follow the company on LinkedIn\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678890-1&h=3948027470&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4637976-1%26h%3D3925258241%26u%3Dhttps%253A%252F%252Fwww.linkedin.com%252Fcompany%252Fneurocrine-biosciences%26a%3DLinkedIn&a=LinkedIn)\n, X\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678890-1&h=1531700774&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4637976-1%26h%3D1809690282%26u%3Dhttps%253A%252F%252Ftwitter.com%252Fneurocrine%26a%3DX&a=X)\n, Facebook\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678890-1&h=2320225458&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4637976-1%26h%3D2235174816%26u%3Dhttps%253A%252F%252Fwww.facebook.com%252FNeurocrine%26a%3DFacebook&a=Facebook)\n and YouTube\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678890-1&h=1434180573&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4637976-1%26h%3D2457028348%26u%3Dhttps%253A%252F%252Fwww.youtube.com%252F%2540NeurocrineBiosciencesInc%26a%3DYouTube&a=YouTube)\n. (*in collaboration with AbbVie)\n\nThe NEUROCRINE BIOSCIENCES Logo, NEUROCRINE, YOU DESERVE BRAVE SCIENCE and\nINGREZZA are registered trademarks of Neurocrine Biosciences, Inc.\n\nForward-Looking Statements\nIn addition to historical facts, this press release contains forward-looking\nstatements that involve a number of risks and uncertainties. These\nstatements include, but are not limited to, statements regarding the potential\nbenefits to be derived from treating patients with tardive dyskinesia (TD)\nwith a vesicular monoamine transporter 2 (VMAT2) inhibitor and the Company's\nplans to encourage awareness that may help address the needs of people living\nwith TD, and the value that such awareness may bring to patients. Factors that\ncould cause actual results to differ materially from those stated or implied\nin the forward-looking statements include, but are not limited to, the\nfollowing: whether the survey findings represent the experiences of people\nliving with TD; whether the Company can successfully encourage awareness that\nmay help address the unmet needs of people living with TD; risks and\nuncertainties associated with Neurocrine Biosciences' business and finances\nin general, as well as risks and uncertainties associated with the\ncommercialization of INGREZZA; whether INGREZZA receives adequate\nreimbursement from third-party payors; risks and uncertainties relating to\ncompetitive products and technological changes that may limit demand for\nINGREZZA; risks associated with the Company's dependence on third parties for\ndevelopment and manufacturing activities related to INGREZZA, and the ability\nof the Company to manage these third parties; risks that additional regulatory\nsubmissions for INGREZZA or other product candidates may not occur or be\nsubmitted in a timely manner; risks that the FDA or other regulatory\nauthorities may make adverse decisions regarding INGREZZA; risks that\npost-approval INGREZZA commitments or requirements may be delayed; risks that\nINGREZZA may be precluded from commercialization by the proprietary or\nregulatory rights of third parties, or have unintended side effects, adverse\nreactions or incidents of misuse; and other risks described in the Company's\nperiodic reports filed with the Securities and Exchange Commission, including\nwithout limitation the Company's annual report on Form 10-K for the year\nended December 31, 2025. Neurocrine Biosciences disclaims any obligation to\nupdate the statements contained in this press release after the date hereof\nother than required by law.\n\nREFERENCES\n\n 1. Ipsos (2026). Tardive Dyskinesia Claims Research Report [Unpublished survey].\nIpsos.\n 2. Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric\nAssociation practice guideline for the treatment of patients with\nschizophrenia. Am J Psychiatry. 2020;177(9):868-872.\ndoi:10.1176/appi.ajp.2020.177901\n 3. Data on file. Neurocrine Biosciences, Inc.\n 4. Ascher-Svanum H, Zhu B, Faries D, Peng X, Kinon BJ, Tohen M. Tardive\ndyskinesia and the 3-year course of schizophrenia: results from a large,\nprospective, naturalistic study. J Clin Psychiatry. 2008;69(10):1580-1588.\ndoi:10.4088/jcp.v69n1008\n 5. Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for\nan increasingly common disorder. Neurotherapeutics. 2014;11(1):166-176.\ndoi:10.1007/s13311-013-0222-5\n© 2026 Neurocrine Biosciences, Inc. All Rights Reserved. CP-TD-US-1569v3\n05/2026\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-new-survey-results-showing-significant-burden-of-tardive-dyskinesia-on-employment-302760554.html\n(https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-new-survey-results-showing-significant-burden-of-tardive-dyskinesia-on-employment-302760554.html)\n\nSOURCE Neurocrine Biosciences, Inc.\n\n\n\nNeurocrine Biosciences, Inc., Media: Aimee White, 1-858-354-7865, media@neurocrine.com; Investors: Todd Tushla, 1-858-617-7143, ir@neurocrine.com\n\nPhoto: \nhttps://mma.prnewswire.com/media/678850/Neurocrine_Biosciences_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn2nbN0Ba","title":"Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment","author":"PR Newswire","ticker":"NBIX","created":"2026-05-04T12:30:03.325Z","tickers":["NBIX"],"exchange":"NASDAQ","article_body":"Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment\n\nPR Newswire\n\nSAN DIEGO, May 4, 2026\n\n * Approximately 1 in 5 surveyed working adults with tardive dyskinesia reported\nquitting their job due to untreated involuntary movements(1)\n * Respondents also reported missing an average of 8 hours of work or school per\nweek due to tardive dyskinesia prior to treatment(1)\n * Findings released during Tardive Dyskinesia Awareness Week\nSAN DIEGO, May 4, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678890-1&h=1463423739&u=https%3A%2F%2Fwww.neurocrine.com%2F&a=Neurocrine+Biosciences%2C+Inc.)\n(Nasdaq: NBIX) today announced the release of findings from a new survey\nrevealing the significant impact of tardive dyskinesia (TD) on people's\nability to work, go to school, volunteer or actively look for employment.\nAbout one in five surveyed working adults with TD reported quitting their job\ndue to TD symptoms prior to treatment.(1) Findings are released in recognition\nof Tardive Dyskinesia Awareness Week (May 3-9) to underscore the importance of\nincreased awareness, early recognition and appropriate management of TD.\n\n(https://mma.prnewswire.com/media/678850/Neurocrine_Biosciences_Logo.html)\n\n\"These findings highlight how uncontrolled, involuntary movements associated\nwith tardive dyskinesia can lead to reduced job responsibilities or even loss\nof employment,\" said Sanjay Keswani, M.D., Chief Medical Officer, Neurocrine\nBiosciences. \"This reinforces the importance of routine screening for tardive\ndyskinesia in clinical practice, including evaluation of its impact on\npatients' and caregivers' lives so that appropriate treatment can be\nconsidered to help reduce this burden.\"\n\nThe quantitative survey was conducted online in the United States by Ipsos on\nbehalf of Neurocrine Biosciences from January 15 to February 17, 2026. It\nincluded 100 individuals: 70 adults (average age 47 years) who have been\ndiagnosed with TD by a healthcare provider and 30 caregivers of people with TD\n(average age 42 years). Employment-related findings are based on the 59\nrespondents diagnosed with TD who met the study's employment criteria*;\ncaregiver burden findings are based on 19 caregivers who completed follow-up\nquestions about the impact of TD on their own lives.(1)\n\nThe survey found that of 59 adults with TD who were working, in school,\nvolunteering or actively looking for employment(1):\n\n * Approximately one in five, or 12 surveyed working adults, reported quitting\ntheir job primarily due to TD symptoms.\n * 19 reported having to step down from their work-related responsibilities or\nchange job responsibilities because of TD symptoms.\n * All 59 respondents reported missing an average of eight hours of work or\nschool during the week prior to starting TD treatment.\nAmong the 19 surveyed working caregivers, many reported missing work or having\ninterruptions to their own lives due to their loved ones' TD symptoms prior to\nstarting treatment.\n\nEarlier screening and accurate diagnosis of TD are critical to ensuring\npatients, who are already managing their underlying serious mental illness,\nreceive appropriate, evidence-based care. The American Psychiatric\nAssociation clinical guidelines recommend first-line, FDA-approved treatment\nwith a vesicular monoamine transporter 2 (VMAT2) inhibitor for those with\nmoderate to severe TD or those with mild TD if the movements are\ndisruptive.(2) Despite these recommendations, only an estimated one out of 10\nindividuals with TD are treated with a VMAT2 inhibitor.(3)\n\n\"Many people may not recognize that their uncontrolled movements are symptoms\nof tardive dyskinesia, which can affect many aspects of everyday life for\nadults, including their ability to work or go to school and, for many\nindividuals, constitutes a key component of their identity,\" said Josie\nCooper, Executive Director of the Movement Disorders Policy Coalition. \"During\nTD Awareness Week, these findings highlight the real-world burden experienced\nby patients and care partners and reinforce why awareness, recognition and\nappropriate management of TD are so important. We hope they encourage people\nto start informed conversations with healthcare providers and seek support.\"\n\nEstablished in 2018, Tardive Dyskinesia Awareness Week unites the mental\nhealth community to recognize the full impact of TD, including its physical,\nsocial and emotional effects on people living with the condition and the need\nfor routine screening, earlier diagnosis and treatment.(4) TD is estimated to\naffect at least 800,000 adults in the U.S. living with mental illness, yet\napproximately 60% remain undiagnosed, meaning many individuals living with TD\nmay not be identified or appropriately managed.(3,5) TD movements can result\nin both physical and emotional consequences, resulting in meaningful burden on\none's employment and ability to maintain work.(1,4) For more information,\nvisit Neurocrine.com/TD-Awareness\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678890-1&h=1851618768&u=https%3A%2F%2Fwww.neurocrine.com%2Ftd-awareness%2F&a=Neurocrine.com%2FTD-Awareness)\n.\n\n*Employment-related findings are based on the low base size of 59 respondents\ndiagnosed with TD who met the study's employment criteria. Exercise caution\nwhen interpreting results.\n\nSurvey Methodology\nThe research was conducted online in the United States by Ipsos on behalf of\nNeurocrine Biosciences among 100 individuals, including 70 people who have\nbeen diagnosed with tardive dyskinesia (TD) by a healthcare provider and 30\ncaregivers of people with TD. Of those individuals, 59 met employment\ncriteria, defined as being currently employed (part time or full time), a\nstudent, a volunteer or unemployed but actively looking for work. Caregivers\nwere defined as a partner/spouse or family member who is not a professional\ncaregiver paid by the patient for their services. The 20-minute quantitative\nonline survey was conducted January 15-February 17, 2026.\n\nAbout Ipsos\nIpsos is one of the largest market research and polling companies globally,\noperating in 90 markets and employing nearly 20,000 people. Ipsos is comprised\nof passionately curious research professionals, analysts and scientists and\nhave built unique multi-specialist capabilities that provide true\nunderstanding and powerful insights into the actions, opinions and motivations\nof citizens, consumers, patients, customers or employees.\n\nAbout Tardive Dyskinesia Awareness Week\nThe first Tardive Dyskinesia (TD) Awareness Week took place in 2018. Over the\nyears, all 50 states, Washington, D.C. and multiple mental health advocacy\norganizations continue to recognize the first full week of May as TD Awareness\nWeek. TD is a chronic condition that is unlikely to improve without treatment\nand is estimated to affect at least 800,000 adults in the United States. TD\nAwareness Week unites the mental health community to recognize the physical,\nsocial and emotional effects of TD and reinforces the importance of early\nassessment by healthcare providers and discussion of available FDA-approved\ntreatment.\n\nNeurocrine Biosciences, Inc. remains focused on TD education, empowering\nindividuals to act and elevating the importance of routine screening for\nearlier diagnosis and appropriate treatment. As part of Neurocrine\nBiosciences' commitment to TD education, more information is available at\nNeurocrine.com/TD-Awareness\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678890-1&h=266837859&u=https%3A%2F%2Fwww.neurocrine.com%2FTD-Awareness%2F&a=Neurocrine.com%2FTD-Awareness)\n, and resources are available at TalkAboutTD.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678890-1&h=3626663216&u=https%3A%2F%2Fwww.talkabouttd.com%2F&a=TalkAboutTD.com)\n. These resources can help patients and care partners understand TD and\nrecognize its symptoms, seek support and have conversations with their\nhealthcare providers about ways to manage the condition, including treatment\noptions. Healthcare professionals can also visit MIND-TD.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678890-1&h=3804491251&u=https%3A%2F%2Fwww.mind-td.com%2F&a=MIND-TD.com)\nto learn about differential diagnosis of TD and other movement disorders. For\nmore information, follow and join the conversation online by sharing\n#TDAwarenessWeek #Screen4TD.\n\nAbout Tardive Dyskinesia\nTardive dyskinesia (TD) is a movement disorder that is characterized by\nuncontrolled, abnormal and repetitive movements of the face, torso and/or\nother body parts, which may be disruptive and negatively impact patients. The\ncondition is associated with taking certain kinds of mental health medicines\n(antipsychotics) that help control dopamine receptors in the brain. Taking\nantipsychotics commonly prescribed to treat mental illnesses such as major\ndepressive disorder, bipolar disorder, schizophrenia and schizoaffective\ndisorder and other prescription medicines (metoclopramide and\nprochlorperazine) used to treat gastrointestinal disorders are associated with\nTD. In patients with TD, these treatments are thought to result in irregular\ndopamine signaling in a region of the brain that controls movement. The\nsymptoms of TD can be mild to severe and are often persistent and\nirreversible. TD is estimated to affect at least 800,000 adults in the U.S.\n\nAbout Neurocrine Biosciences, Inc.\nNeurocrine Biosciences is a leading biopharmaceutical company with a simple\npurpose: to relieve suffering for people with great needs. We are dedicated to\ndiscovering and developing life-changing treatments for patients with\nunder-addressed neurological, endocrine, psychiatric and immunological\ndisorders. The company's diverse portfolio includes FDA-approved treatments\nfor tardive dyskinesia, chorea associated with Huntington's disease, classic\ncongenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well\nas a robust pipeline including multiple compounds in mid- to late-phase\nclinical development across our core therapeutic areas. For three decades, we\nhave applied our unique insight into neuroscience and the interconnections\nbetween brain and body systems to treat complex conditions. We relentlessly\npursue medicines to ease the burden of debilitating diseases and disorders\nbecause you deserve brave science. For more information, visit neurocrine.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678890-1&h=1504702785&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4637976-1%26h%3D778289524%26u%3Dhttps%253A%252F%252Fwww.neurocrine.com%252F%26a%3Dneurocrine.com&a=neurocrine.com)\n, and follow the company on LinkedIn\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678890-1&h=3948027470&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4637976-1%26h%3D3925258241%26u%3Dhttps%253A%252F%252Fwww.linkedin.com%252Fcompany%252Fneurocrine-biosciences%26a%3DLinkedIn&a=LinkedIn)\n, X\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678890-1&h=1531700774&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4637976-1%26h%3D1809690282%26u%3Dhttps%253A%252F%252Ftwitter.com%252Fneurocrine%26a%3DX&a=X)\n, Facebook\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678890-1&h=2320225458&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4637976-1%26h%3D2235174816%26u%3Dhttps%253A%252F%252Fwww.facebook.com%252FNeurocrine%26a%3DFacebook&a=Facebook)\n and YouTube\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678890-1&h=1434180573&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4637976-1%26h%3D2457028348%26u%3Dhttps%253A%252F%252Fwww.youtube.com%252F%2540NeurocrineBiosciencesInc%26a%3DYouTube&a=YouTube)\n. (*in collaboration with AbbVie)\n\nThe NEUROCRINE BIOSCIENCES Logo, NEUROCRINE, YOU DESERVE BRAVE SCIENCE and\nINGREZZA are registered trademarks of Neurocrine Biosciences, Inc.\n\nForward-Looking Statements\nIn addition to historical facts, this press release contains forward-looking\nstatements that involve a number of risks and uncertainties. These\nstatements include, but are not limited to, statements regarding the potential\nbenefits to be derived from treating patients with tardive dyskinesia (TD)\nwith a vesicular monoamine transporter 2 (VMAT2) inhibitor and the Company's\nplans to encourage awareness that may help address the needs of people living\nwith TD, and the value that such awareness may bring to patients. Factors that\ncould cause actual results to differ materially from those stated or implied\nin the forward-looking statements include, but are not limited to, the\nfollowing: whether the survey findings represent the experiences of people\nliving with TD; whether the Company can successfully encourage awareness that\nmay help address the unmet needs of people living with TD; risks and\nuncertainties associated with Neurocrine Biosciences' business and finances\nin general, as well as risks and uncertainties associated with the\ncommercialization of INGREZZA; whether INGREZZA receives adequate\nreimbursement from third-party payors; risks and uncertainties relating to\ncompetitive products and technological changes that may limit demand for\nINGREZZA; risks associated with the Company's dependence on third parties for\ndevelopment and manufacturing activities related to INGREZZA, and the ability\nof the Company to manage these third parties; risks that additional regulatory\nsubmissions for INGREZZA or other product candidates may not occur or be\nsubmitted in a timely manner; risks that the FDA or other regulatory\nauthorities may make adverse decisions regarding INGREZZA; risks that\npost-approval INGREZZA commitments or requirements may be delayed; risks that\nINGREZZA may be precluded from commercialization by the proprietary or\nregulatory rights of third parties, or have unintended side effects, adverse\nreactions or incidents of misuse; and other risks described in the Company's\nperiodic reports filed with the Securities and Exchange Commission, including\nwithout limitation the Company's annual report on Form 10-K for the year\nended December 31, 2025. Neurocrine Biosciences disclaims any obligation to\nupdate the statements contained in this press release after the date hereof\nother than required by law.\n\nREFERENCES\n\n 1. Ipsos (2026). Tardive Dyskinesia Claims Research Report [Unpublished survey].\nIpsos.\n 2. Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric\nAssociation practice guideline for the treatment of patients with\nschizophrenia. Am J Psychiatry. 2020;177(9):868-872.\ndoi:10.1176/appi.ajp.2020.177901\n 3. Data on file. Neurocrine Biosciences, Inc.\n 4. Ascher-Svanum H, Zhu B, Faries D, Peng X, Kinon BJ, Tohen M. Tardive\ndyskinesia and the 3-year course of schizophrenia: results from a large,\nprospective, naturalistic study. J Clin Psychiatry. 2008;69(10):1580-1588.\ndoi:10.4088/jcp.v69n1008\n 5. Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for\nan increasingly common disorder. Neurotherapeutics. 2014;11(1):166-176.\ndoi:10.1007/s13311-013-0222-5\n© 2026 Neurocrine Biosciences, Inc. All Rights Reserved. CP-TD-US-1569v3\n05/2026\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-new-survey-results-showing-significant-burden-of-tardive-dyskinesia-on-employment-302760554.html\n(https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-new-survey-results-showing-significant-burden-of-tardive-dyskinesia-on-employment-302760554.html)\n\nSOURCE Neurocrine Biosciences, Inc.\n\n\n\nNeurocrine Biosciences, Inc., Media: Aimee White, 1-858-354-7865, media@neurocrine.com; Investors: Todd Tushla, 1-858-617-7143, ir@neurocrine.com\n\nPhoto: \nhttps://mma.prnewswire.com/media/678850/Neurocrine_Biosciences_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-05-04T12:30:03.367264651Z","server_sent_at_ms":1777897803367},"received_at":"2026-05-04T12:30:03.595Z","source_url":"https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-new-survey-results-showing-significant-burden-of-tardive-dyskinesia-on-employment-302760554.html"},"analysis":{"id":"17258","press_release_id":"19015","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Neurocrine released survey data showing significant employment impacts of tardive dyskinesia (TD), with 1 in 5 working adults quitting jobs due to symptoms and respondents missing 8 hours of work/school weekly prior to treatment.\n\nThe findings, released during Tardive Dyskinesia Awareness Week, support the use of FDA-approved VMAT2 inhibitors like INGREZZA to reduce this burden.\n\nThe company emphasizes the need for earlier diagnosis and routine screening, noting that only an estimated 1 in 10 individuals with TD are currently treated with a VMAT2 inhibitor.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Survey data reinforces commercial narrative for INGREZZA, but lacks material financial or clinical updates."},"keyFigures":{"customDimensions":{"survey_respondents_td":70,"survey_respondents_total":100,"patients_quitting_job_pct":"20%","survey_respondents_caregivers":30,"patients_missed_work_hours_week":"8","survey_respondents_employment_criteria":59}},"quotedText":"These findings highlight how uncontrolled, involuntary movements associated with tardive dyskinesia can lead to reduced job responsibilities or even loss of employment","namedEntities":{"people":[{"name":"Sanjay Keswani","role":"Chief Medical Officer"},{"name":"Josie Cooper","role":"Executive Director of the Movement Disorders Policy Coalition"}],"products":["INGREZZA","VMAT2 inhibitor"],"companies":[{"name":"Neurocrine Biosciences, Inc.","ticker":"NBIX"},{"name":"Ipsos","relationship":"survey conductor"},{"name":"Movement Disorders Policy Coalition","relationship":"partner"},{"name":"American Psychiatric Association","relationship":"guideline issuer"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Issuer-sponsored survey highlighting the burden of Tardive Dyskinesia (TD) on employment, reinforcing the need for treatment with VMAT2 inhibitors (Neurocrine's class of drug). While supportive of the commercial thesis for INGREZZA, it is non-financial, contains no clinical trial results, and is primarily a marketing/awareness effort."},"tickerRelevance":{"others":[],"primary":"NBIX"},"globalImportance":10,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"corporate-sponsored survey","sectorWeight":"biotech","financialImpact":"none"}},"event_type":"other","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Neurocrine released survey data showing significant employment impacts of tardive dyskinesia (TD), with 1 in 5 working adults quitting jobs due to symptoms and respondents missing 8 hours of work/school weekly prior to treatment.\n\nThe findings, released during Tardive Dyskinesia Awareness Week, support the use of FDA-approved VMAT2 inhibitors like INGREZZA to reduce this burden.\n\nThe company emphasizes the need for earlier diagnosis and routine screening, noting that only an estimated 1 in 10 individuals with TD are currently treated with a VMAT2 inhibitor.","key_figures":{"customDimensions":{"survey_respondents_td":70,"survey_respondents_total":100,"patients_quitting_job_pct":"20%","survey_respondents_caregivers":30,"patients_missed_work_hours_week":"8","survey_respondents_employment_criteria":59}},"named_entities":{"people":[{"name":"Sanjay Keswani","role":"Chief Medical Officer"},{"name":"Josie Cooper","role":"Executive Director of the Movement Disorders Policy Coalition"}],"products":["INGREZZA","VMAT2 inhibitor"],"companies":[{"name":"Neurocrine Biosciences, Inc.","ticker":"NBIX"},{"name":"Ipsos","relationship":"survey conductor"},{"name":"Movement Disorders Policy Coalition","relationship":"partner"},{"name":"American Psychiatric Association","relationship":"guideline issuer"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:6c7fa2f5e3b62e83","schema_hash":"sha256:ee8f711bc9bfba0d","created_at":"2026-05-06T16:13:25.454Z","global_importance":10,"audience_relevance":25,"importance_components":{"tickerTier":"mid-cap","eventGravity":"corporate-sponsored survey","sectorWeight":"biotech","financialImpact":"none"}},"durationMs":null,"modelName":"glm-4.7"}}